Carcinoma in Situ  >>  bizalimogene ralaplasmid (VGX-3100)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bizalimogene ralaplasmid (VGX-3100) / Inovio
NCT01304524 / 2012-001334-33: A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

Completed
2
167
Canada, US, Europe, RoW
VGX 3100, Placebo, CELLECTRA™-5P
Inovio Pharmaceuticals
Cervical Intraepithelial Neoplasia
05/14
04/15

Download Options